Intra-individual Dose Escalation of Abiraterone Acetate According to Its Plasma Concentration in Patients With Progressive Castration-resistant Metastatic Prostate Cancer
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms OPTIMABI
- 03 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.
- 01 Mar 2018 Status changed from recruiting to not yet recruiting.
- 15 Jan 2018 New trial record